الفهرس 
Acute myeloid leukemiaOnly 14 pages are availabe for public view
 |  | from | 91 |  |  |
| | | from | 91 | | |
Abstract
ABSTRACT
BackgroundAcute myeloid leukemia (AML) is an aggressive type of blood cancer affecting bone marrow (BM). In AML, hematopoietic precursors are arrested in the early stages of development and are defined as the presence of ≥ 20% blasts (leukemia cells) in the BM
Aim of the Work: This work aims to study the relation between resistance to treatment in acute myeloid leukemia cases and presence of RUNX1 mutations..
Patients and Methods: This study was conducted on 50 patients including 30 newly diagnosed adult acute myeloid leukemia patients after receiving conventional chemotherapy protocols (Day 28) (according to NCCN guidelines for AML) and not responding to first induction of treatment (group I). And 20 newly diagnosed AML cases after receiving the same conventional induction chemotherapy with complete remission at (Day 28) as a control group (group II).
Results: The study included 50 subjects, 30 newly diagnosed adult AML (group I) patients after receiving conventional first induction chemotherapy protocol, and not responding to first induction chemotherapy, and 20 newly diagnosed AML cases after receiving the same conventional induction chemotherapy and proved complete remission as a control group (group II). All included subjects received the same induction protocol (3+7 protocol. except M3 patients who received induction by Pethema protocol.
Conclusion: In this study we put spot light on the significance of RUNX1 mutation and it is role in resistance to induction chemotherapy which affecting prognosis of treatment in de Novo AML patients. We found that AML with RUNX1 gene mutations is associated with poorer response to conventional chemotherapy, lower rates of complete remission (CR), relapse free survival (RFS), and overall survival (OS).